ITMN—I interpret the news as Roche’s agreeing to pay $175M merely to be free and clear of contractual obligations stemming from the 2006 Roche-ITMN partnership for HCV protease inhibitors. Inasmuch as there are newer and better PI’s available, I doubt that Roche will advance ITMN-191 to phase-3.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.